Anticoagulant Reversal Drugs Market Size & CAGR (2023-2031)
The Anticoagulant Reversal Drugs Market size is projected to reach US$ 2,442.87 million by 2031 from US$ 1306.40 million in 2023. The market is expected to register a CAGR of 10.08% in 2023–2031. Development and launch of innovative products are likely to remain key anticoagulant reversal drugs market trends.
Anticoagulant Reversal Drugs Market Analysis
In recent years, the use of anticoagulants has increased for preventing and treating various cardiovascular conditions such as pulmonary embolism (PE), deep vein thrombosis (DVT), atrial fibrillation (AF), mechanical heart valve thrombosis, and acute coronary syndromes. However, the widespread use of these treatments carries the risk of major and minor bleeding, leading to hospitalizations and emergency department visits. This risk can increase if patients are prescribed combination therapy consisting of an anticoagulant and antiplatelet or dual antiplatelet therapy. When used alone, warfarin and aspirin have the highest bleeding risk. Thus, anticoagulant reversal drugs are used to prevent bleeding. The rise in the prevalence of atrial fibrillation (AFib) and the increase in incidences of stroke are expected to favor the development of new treatments to improve speech.
Anticoagulant Reversal Drugs Market Overview
As highlighted by the Centers for Disease Control and Prevention (CDC), every year, more than 454,000 AFib-related hospitalizations occur in the US, resulting in about 158,000 deaths. Additionally, the risk of developing AFib increases with age, and high blood pressure, which also becomes more common with advancing age, is a factor in ~ 1 out of every 5 cases of AFib. The rising geriatric population is expected to bring an uptake in the demand for anticoagulant reversal drugs in the coming decade.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Anticoagulant Reversal Drugs Market: Strategic Insights
Market Size Value in US$ 922.55 Million in 2019 Market Size Value by US$ 2,276.54 Million by 2027 Growth rate CAGR of 12.6% from 2020-2027 Forecast Period 2020-2027 Base Year 2020
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Anticoagulant Reversal Drugs Market: Strategic Insights
| Market Size Value in | US$ 922.55 Million in 2019 |
| Market Size Value by | US$ 2,276.54 Million by 2027 |
| Growth rate | CAGR of 12.6% from 2020-2027 |
| Forecast Period | 2020-2027 |
| Base Year | 2020 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Anticoagulant Reversal Drugs Market Drivers and Opportunities
Mounting Neurodegenerative Diseases and Speech Disorders to Favor Market
Anticoagulant reversal drugs are used in the management of hemorrhagic stroke to decrease ongoing bleeding and allow tissues to recover. There has been an increase in stroke prevalence in low- and middle-income countries. According to the Stroke Awareness Foundation, ~ 795,000 individuals suffer from a stroke each year in the US, accounting for over 140,000 deaths each year. Out of this number, ~ 40% of stroke-related deaths occur in males, while the remaining 60% occur in females. In an article published by Annals of Palliative Medicine (APM) in May 2021, a combination of 4-factor prothrombin complex concentrate, fresh frozen plasma, and vitamin K1 was administered in a patient under warfarin treatment who suffered from acute ischemic stroke (AIS). The report showed neurological improvement and successful reversal of coagulation regarding AIS patients with warfarin-related hypercoagulability. Therefore, propelling incidences of stroke are a major driver of anticoagulant reversal drugs market share.
Increasing Research Activities – An Opportunity in the Development of Novel Anticoagulant Reversal Drugs
Rapidly progressing research activities in drug development of novel therapeutics worldwide to counter the growing prevalence of cardiovascular diseases, such as atrial fibrillation, are driving the growth of the anticoagulant reversal drugs market. There is always a need for innovative therapeutic approaches in the treatment of various cardiovascular indications. For instance, the study titled ‘Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages,’ published in July 2020 in the Journal of Thrombosis and Haemostasis, was conducted in Massachusetts General Hospital, to investigate the efficacy of andexanet alfa in the treatment of intracranial hemorrhages (ICH). Thus, the increasing number of research activities is boosting drug discovery activities and offering lucrative opportunities for market growth across the industry.
Anticoagulant Reversal Drugs Market Report Segmentation Analysis
Key segments that contributed to the derivation of the anticoagulant reversal drugs market analysis are product and distribution channel.
- Based on product, the anticoagulant reversal drugs Market is divided into prothrombin complex concentrates, vitamin K, protamine, tranexamic acid, idarucizumab, and AndeXXa. The prothrombin complex concentrates segment held the largest share of the market in 2023.
- In terms of distribution channel, the anticoagulant reversal drugs market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2023.
Anticoagulant Reversal Drugs Market Share Analysis by Geography
The geographic scope of the anticoagulant reversal drugs Market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America has dominated the anticoagulant reversal drugs market. In North America, the US is the largest market for anticoagulant reversal drugs. The growth of this market is primarily driven by the growing prevalence of cardiovascular diseases such as atrial fibrillation, developments by the market players, and the presence of major market players in the US will accelerate the growth of this market in this country. Also, strategic developments by the market players in the US are likely to favor the growth of the market. For instance, in June 2023, AstraZeneca proceeded with full regulatory filings for its Andexxa (andexanet alfa) in the US and EU, moving ahead from the current conditional approval. Andexxa is a treatment that can quickly reverse the anticoagulation effects of direct oral FXa inhibitors. Over 15 national and international guidelines across multiple disciplines support its use. AstraZeneca now proceeded with regulatory filings for full label approval in the US.
Anticoagulant Reversal Drugs Market Report Scope
Anticoagulant Reversal Drugs Market News and Recent Developments
The anticoagulant reversal drugs market is evaluated by gathering qualitative and quantitative data from primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for speech and language disorders and strategies:
- AstraZeneca Pharma India Ltd. announced that it received approval from the Central Drugs Standard Control Organisation (CDSCO) in India to import and market Andexanet Alfa. This treatment is effective in addressing life-threatening or refractory bleeding that comes with the use of Factor Xa (FXa) inhibitors. (Source: AstraZeneca Pharma, Press Release, 2024)
- Octapharma USA announced the approval of Balfaxar from the US Food and Drug Administration (FDA). Balfaxar is a non-activated four-factor prothrombin complex concentrate (4F-PCC) containing vitamin K-dependent factors: Factor II (prothrombin), Factor VII, Factor IX, and Factor X, and antithrombotic Proteins C and S. It can be used to urgently reverse acquired coagulation factor deficiency induced by vitamin K antagonist (VKA) therapy in adult patients who require urgent surgery or invasive procedures. Balfaxar helps restore blood coagulation by replenishing the levels of deficient clotting factors due to warfarin therapy. (Source: Octapharma USA, Inc, Press Release, 2023)
Anticoagulant Reversal Drugs Market Report Coverage and Deliverables
The “Anticoagulant Reversal Drugs Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
- Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Market dynamics such as drivers, restraints, and key opportunities
- Key future trends
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product , and Distribution channel and Geography.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For